| identifier: | 1817116 |
| description: |
epitope description:alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)-[alpha-N-acetylneuraminosyl-(2->3)]-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine
host organism:Homo sapiens
|
| aggregation: |
instance of dataset
|
| availability: |
available
|
| primaryPublications: |
11574105 |
| authorizations: |
registration not required
|
| accessURL: |
http://www.iedb.org/reference/1018069 |
| landingPage: |
http://www.iedb.org/assay/1817116 |
| type: |
Literature
|
| publicationVenue: |
J Neurol Sci
|
| dates: |
2001
|
| study type: | b cell assays |
| subject species: | Homo sapiens |
| fullName: |
R Press
S Matá
F Lolli
J Zhu
T Andersson
H Link
|
| method: |
ELISA
|
| name: |
Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
|
| description: |
In some patients, antibody levels rose steadily to a peak at Day 40 or 90 after disease onset, then decreased. In other patients, levels remained stable. Patients with antibody peaks had higher disability scores and worse clinical outcomes and axonal damage compared to patients without peak antibody titers.
|
| name: |
iedb
|
| homePage: |
http://www.iedb.org |